Department of Orthopaedic Surgery, Baylor College of Medicine, Houston, TX, USA.
Fondren Orthopedic Group, Texas Orthopedic Hospital, Houston, TX, USA; Fondren Orthopedic Research Institute (FORI), Houston, TX, USA; Texas Education and Research Foundation for Shoulder and Elbow Surgery, Inc. (TERFSES), Houston, TX, USA.
J Shoulder Elbow Surg. 2020 Dec;29(12):2571-2577. doi: 10.1016/j.jse.2020.03.050. Epub 2020 Jun 9.
Glenoid component malpositioning and glenoid component retroversion have been associated with higher rates of radiolucencies, raising concerns about its implications on glenoid loosening and ultimate failure of anatomic total shoulder arthroplasty (TSA). Although there is literature regarding the relative advantages of techniques to address posterior glenoid bone loss, we are not aware of studies comparing outcomes of TSA on these challenging Walch type B2 glenoids vs. more common A1 glenoids. The purpose of this study is to compare outcomes of TSA performed on A1 glenoids and B2 glenoids treated with asymmetric glenoid reaming.
We identified 1045 shoulders that had primary TSAs performed for osteoarthritis in a prospective shoulder arthroplasty registry. Two hundred eighty-nine shoulders met inclusion criteria of a preoperative Walch type A1 (178) or B2 (111) glenoid morphology, treatment with TSA, asymmetric reaming in the B2 group, and a minimum of 2-year clinical and radiographic follow-up. Postoperative radiographs were assessed for lucencies, and patient-reported outcome measures were collected at all follow-up visits.
Follow-up averaged 40 ± 15 months for all patients, and more men presented with a B2 glenoid (80 of 111; 72%) compared with A1 (101 of 178; 57%) (P = .009). Age at surgery (P = .166), dominant-sided surgery (P = .281), body mass index (P = .501), smoking (P = .155), preoperative opioid use (P = .154), and diabetes (P = .331) were not significantly different between groups. Both groups had similar Constant Strength scores preoperatively (A1: 4.7 ± 7.1, and B2: 4.3 ± 7.3) but the B2 group improved significantly more at final follow-up (A1: 10.3 ± 6.2 vs. B2: 12.7 ± 6.7, P = .005). The Total Constant score was also significantly better at follow-up in the B2 glenoid group (P = .039). All other Constant subscales, American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES), and Single Assessment Numerical Evaluation (SANE) measures showed significant improvement preoperatively to final follow-up (all P <.001) but there were no significant differences between the A1 and B2 glenoid groups (all P > .05). A similar proportion of patients rated their satisfaction as either very satisfied or satisfied between the A1 (160; 90%) and B2 (100; 90%) (P = .613). Lazarus scores were also similar between the A1 and B2 groups (P = .952) as were the rates of humeral radiolucent lines (P = .749) and humeral osteolysis (P = .507).
Although patients with B2 glenoids may present a more technically challenging anatomic total shoulder arthroplasty, treatment with concurrent asymmetric glenoid reaming produced similar, successful clinical and radiographic early to midterm outcomes for patients undergoing TSA compared with A1 glenoids. Additional follow-up on this cohort will be important to confirm the durability of these early results.
肩盂假体位置不良和肩盂假体后倾与更高的透亮线率有关,这引发了对其对肩盂松动和解剖全肩关节置换术(TSA)最终失败影响的担忧。尽管有关于解决后盂骨丢失的技术的相关优势的文献,但我们不知道比较在这些具有挑战性的 Walch 型 B2 盂和更常见的 A1 盂上进行 TSA 治疗结果的研究。本研究的目的是比较在 A1 盂和 B2 盂上进行 TSA 的结果,B2 盂采用非对称盂扩孔治疗。
我们在一个前瞻性肩关节置换登记处确定了 1045 例因骨关节炎接受初次 TSA 的肩关节。289 例符合术前 Walch 型 A1(178 例)或 B2(111 例)盂形态、接受 TSA 治疗、B2 组行非对称盂扩孔以及至少 2 年临床和影像学随访的纳入标准。术后 X 线片评估透亮线,并在所有随访时收集患者报告的结果测量。
所有患者的平均随访时间为 40 ± 15 个月,与 A1(101 例中有 80 例,57%)相比,B2(111 例中有 80 例,72%)组中更多的患者存在 B2 盂(P =.009)。手术时的年龄(P =.166)、优势侧手术(P =.281)、体重指数(P =.501)、吸烟(P =.155)、术前阿片类药物使用(P =.154)和糖尿病(P =.331)在两组之间无显著差异。两组术前的 Constant 力量评分相似(A1:4.7 ± 7.1,B2:4.3 ± 7.3),但 B2 组在最终随访时明显改善(A1:10.3 ± 6.2 对 B2:12.7 ± 6.7,P =.005)。B2 盂组的总 Constant 评分在随访时也明显更好(P =.039)。所有其他 Constant 子量表、美国肩肘外科医生标准化肩关节评估表(ASES)和单评估数字评估(SANE)测量值在术前至最终随访时均显著改善(均 P <.001),但 A1 盂和 B2 盂组之间无显著差异(均 P >.05)。在 A1(160 例中有 100 例,90%)和 B2(111 例中有 100 例,90%)盂中,相似比例的患者对其满意度评为非常满意或满意(P =.613)。A1 盂和 B2 盂组的 Lazarus 评分也相似(P =.952),肱骨透亮线率(P =.749)和肱骨溶骨率(P =.507)也相似。
尽管 B2 盂患者可能存在更具技术挑战性的解剖全肩关节置换术,但采用同期非对称盂扩孔治疗与 A1 盂相比,可使接受 TSA 治疗的患者获得相似的、成功的临床和影像学早期至中期结果。对该队列进行更多的随访将有助于证实这些早期结果的耐久性。